dNLR-Based Score Predicting Overall Survival Benefit for The Addition of Platinum-Based Chemotherapy to Pembrolizumab in Advanced NSCLC With PD-L1 Tumor Proportion Score ≥50%
Titel:
dNLR-Based Score Predicting Overall Survival Benefit for The Addition of Platinum-Based Chemotherapy to Pembrolizumab in Advanced NSCLC With PD-L1 Tumor Proportion Score ≥50%
Auteur:
Holtzman, Liran Moskovitz, Mor Urban, Damien Nechushtan, Hovav Keren, Shoshana Reinhorn, Daniel Wollner, Mira Daher, Sameh Rottenberg, Yakir Rovitzky, Yulia Shochat, Tzippy Bar, Jair Dudnik, Elizabeth